ImmuPharma plc (LON:IMM – Get Free Report) rose 21.4% during trading on Monday . The company traded as high as GBX 4.95 ($0.06) and last traded at GBX 4.78 ($0.06). Approximately 22,028,340 shares changed hands during mid-day trading, an increase of 11% from the average daily volume of 19,813,568 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Stock Performance
The company has a market cap of £19.57 million, a price-to-earnings ratio of -470.00 and a beta of 1.53. The company’s fifty day moving average is GBX 1.92 and its two-hundred day moving average is GBX 1.78.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Buy P&G Now, Before It Sets A New All-Time High
- What Does the Future Hold for Eli Lilly?
- P/E Ratio Calculation: How to Assess Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
